Your browser doesn't support javascript.
loading
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Pontes, Caridad; Zara, Corinne; Torrent-Farnell, Josep; Obach, Merce; Nadal, Cristina; Vella-Bonanno, Patricia; Ermisch, Michael; Simoens, Steven; Hauegen, Renata Curi; Gulbinovic, Jolanta; Timoney, Angela; Martin, Antony P; Mueller, Tanja; Nachtnebel, Anna; Campbell, Stephen; Selke, Gisbert; Bochenek, Tomasz; Rothe, Celia C; Mardare, Ileana; Bennie, Marion; Fürst, Jurij; Malmstrom, Rickard E; Godman, Brian.
Afiliação
  • Pontes C; Drug Area, Catalan Health Service, Travessera de les Corts 131, Edifici Olimpia, 08028, Barcelona, Spain. cpontes@catsalut.cat.
  • Zara C; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain. cpontes@catsalut.cat.
  • Torrent-Farnell J; Drug Area, Catalan Health Service, Travessera de les Corts 131, Edifici Olimpia, 08028, Barcelona, Spain.
  • Obach M; Drug Area, Catalan Health Service, Travessera de les Corts 131, Edifici Olimpia, 08028, Barcelona, Spain.
  • Nadal C; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Vella-Bonanno P; Drug Area, Catalan Health Service, Travessera de les Corts 131, Edifici Olimpia, 08028, Barcelona, Spain.
  • Ermisch M; Catalan Health Service, Barcelona, Spain.
  • Simoens S; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Hauegen RC; Pharmaceutical Department, National Association of Statutory Health Insurance Funds, Berlin, Germany.
  • Gulbinovic J; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Timoney A; National Institute of Science and Technology for Innovation on Diseases of Neglected Populations (INCT-IDPN), Center for Technological Development in Health (CDTS), Osvaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
  • Martin AP; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Mueller T; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Nachtnebel A; NHS Lothian, Edinburgh, UK.
  • Campbell S; Health Economics Centre, University of Liverpool Management School, Liverpool, UK.
  • Selke G; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Bochenek T; Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Austria.
  • Rothe CC; Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
  • Mardare I; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK.
  • Bennie M; Wissenschaftliches Institut der AOK (WidO), Berlin, Germany.
  • Fürst J; Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland.
  • Malmstrom RE; Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland.
  • Godman B; Department of Public Health and Management, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Appl Health Econ Health Policy ; 18(1): 5-16, 2020 02.
Article em En | MEDLINE | ID: mdl-31696433
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Aprovação de Drogas / Antibióticos Antineoplásicos / Anticorpos Monoclonais / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Aprovação de Drogas / Antibióticos Antineoplásicos / Anticorpos Monoclonais / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article